AIMT News and Press, Aimmune Therapeutics Inc. From 01/21/20

Aimmune Therapeutics, Inc. ( AIMT ) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. B...

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...

Aimmune Therapeutics '  (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allerg...

Shares of DBV Technologies (NASDAQ: DBVT) are up 11% at 12:40 p.m. EST on positive long-term data for the biotech 's peanut allergy medication Viaskin Peanut. Children in the phase 3 Pepites clinical trial were able to continue on the drug in an extension study called People. After three y...

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38 th Annual J.P. Morgan Healthcare Conferenc...

Aimmune Therapeutics, Inc. (AIMT) has been quite a sprightly stock lately, and it has a couple of key events coming up as well. However, the firm also faces a few obstacles, the foremost being the FDA's stepmotherly attitude over the years. Its lead drug candidate Palforzia was approved by t...

Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Does the management have a determination to continue to develop products or processes that will further increase total sales potentials when the growth potentials of currently attractive product lines have largely been exploited? - Philip Fisher If you've been following my blog , you'...